Aratana Therapeutics Reports Second Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Aratana Therapeutics (PETX) Tops Q2 EPS by 37c
August 4, 2016 4:21 PM EDTAratana Therapeutics (NASDAQ: PETX) reported Q2 EPS of $0.61, $0.37 better than the analyst estimate of $0.24. Revenue for the quarter came in at $38.05 million versus the consensus estimate of $7.61 million.
For earnings history and earnings-related data on Aratana Therapeutics (PETX) click here.
... More